{
    "nct_id": "NCT05496829",
    "official_title": "IMPACT Trial: Intervention to IMProve AdherenCe Equitably",
    "inclusion_criteria": "* Women or men age >18 years\n* Diagnosed with stage I-III breast cancer prescribed endocrine therapy\n* Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)\n* Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention\n* Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Evidence of breast cancer recurrence\n* Non-English or Non-Spanish speaking\n* Not cognitively able to complete study requirements\n* Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR\n* Inability to provide informed consent",
    "miscellaneous_criteria": ""
}